Table 1.

Baseline characteristics

Baseline characteristicsStudy cohort (n = 24)
Median age (range)59 (42–77)
Gender
 Male8 (33%)
 Female16 (67%)
Race/ethnicity
 Caucasian19
 Asian3
 African American1
 Hispanic1
ECOG performance status
 06 (25%)
 124 (75%)
Tumor histology
 Breast11 (46%)
 Prostate5 (21%)
 Ovarian2 (8%)
 Cancer of unknown primary2 (8%)
 Cholangiocarcinoma2 (8%)
 Other*2 (8%)
Number of lines of prior therapy
 00
 13 (12%)
 23 (12%)
 33(12%)
 45 (21%)
 55(21%)
 ≥65 (21%)
Prior platinum therapy14 (58%)
Progressed on platinum8 (33%)
Prior PARP inhibitor1 (4%)
Genetic mutations
 Germline BRCA1/27 (29%)
 Somatic mutations in DNA repair3 (12%)
 VUS in DNA repair (somatic/germline)6 (25%)
 Unknown4 (16%)
 Negative4 (16%)
Patient disposition
Reasons for study discontinuation, n (%)
 Disease progression19 (79%)
 Unacceptable toxicity3 (12.5%)
 Unrelated adverse event1 (4%)
 Therapy ongoing1 (4%)
  • *Other cancers: Adenoid cystic carcinoma and urothelial carcinoma.